Assessment of efficacy and safety of anlotinib combined with gefitinib in stage III B-Ⅳ EGFR gene mutant non-small cell lung cancer patients with slow progress
Latest Information Update: 08 Jul 2021
At a glance
- Drugs Catequentinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Jul 2021 New trial record
- 08 Jun 2021 Results (N=15), presented at the 57th Annual Meeting of the American Society of Clinical Oncology